Jaks and cytokine receptors--an intimate relationship.
暂无分享,去创建一个
Stephanie Kreis | I. Behrmann | S. Kreis | C. Margue | Iris Behrmann | Claude Haan | Christiane Margue | C. Haan
[1] P. Heinrich,et al. The Jak1 SH2 Domain Does Not Fulfill a Classical SH2 Function in Jak/STAT Signaling but Plays a Structural Role for Receptor Interaction and Up-regulation of Receptor Surface Expression* , 2005, Journal of Biological Chemistry.
[2] M. Shibamori,et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. , 2000, Immunity.
[4] I. Kerr,et al. Jaks and Stats in signaling by the cytokine receptor superfamily. , 1995, Trends in genetics : TIG.
[5] R. Schreiber,et al. Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.
[6] Hong-Jian Zhu,et al. A Pivotal Role for the Transmembrane Domain in Transforming Growth Factor-β Receptor Activation* , 1999, The Journal of Biological Chemistry.
[7] A. Wilks,et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase , 1991, Molecular and cellular biology.
[8] Stefan N. Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.
[9] A. Ullrich,et al. Proline-rich Sequence-mediated Jak2 Association to the Prolactin Receptor Is Required but Not Sufficient for Signal Transduction (*) , 1995, The Journal of Biological Chemistry.
[10] B. Klein,et al. Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb. , 1998, International immunology.
[11] H. Nakauchi,et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. , 1995, Immunity.
[12] O. Silvennoinen,et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin , 1993, Cell.
[13] I. Wilson,et al. Erythropoietin receptor activation by a ligand-induced conformation change. , 1999, Science.
[14] J. Girault,et al. Janus Kinases and Focal Adhesion Kinases Play in the 4.1 Band: A Superfamily of Band 4.1 Domains Important for Cell Structure and Signal Transduction , 1998, Molecular medicine.
[15] I. Wilson,et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. , 1999, Science.
[16] J. Johnston,et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) , 1995, Nature.
[17] A. Alcover,et al. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression , 2003, The EMBO journal.
[18] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[19] M. Fellous,et al. Specific Contribution of Tyk2 JH Regions to the Binding and the Expression of the Interferon α/β Receptor Component IFNAR1* , 1998, The Journal of Biological Chemistry.
[20] P. Heinrich,et al. Orientational Constraints of the gp130 Intracellular Juxtamembrane Domain for Signaling* , 2002, The Journal of Biological Chemistry.
[21] S. Constantinescu,et al. Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability* , 2005, Journal of Biological Chemistry.
[22] J. O’Shea,et al. Jak3-Independent Trafficking of the Common γ Chain Receptor Subunit: Chaperone Function of Jaks Revisited , 2004, Molecular and Cellular Biology.
[23] N. Danial,et al. Jak-STAT signaling induced by the v-abl oncogene. , 1995, Science.
[24] P. Bates,et al. A region encompassing the FERM domain of Jak1 is necessary for binding to the cytokine receptor gp130 , 2001, FEBS letters.
[25] J. Marine,et al. Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.
[26] D. Waxman,et al. Interaction of Growth Hormone-activated STATs with SH2-containing Phosphotyrosine Phosphatase SHP-1 and Nuclear JAK2 Tyrosine Kinase* , 1997, The Journal of Biological Chemistry.
[27] W. Leonard,et al. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta. , 1998, The Journal of biological chemistry.
[28] P. Karplus,et al. Structure of the ERM Protein Moesin Reveals the FERM Domain Fold Masked by an Extended Actin Binding Tail Domain , 2000, Cell.
[29] J. Roberts,et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. , 2001, Molecular cell.
[30] T. Boggon,et al. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. , 2005, Blood.
[31] P. Changelian,et al. The Novel JAK‐3 Inhibitor CP‐690550 Is a Potent Immunosuppressive Agent in Various Murine Models , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[32] B. Han,et al. Protein 4.1R core domain structure and insights into regulation of cytoskeletal organization , 2000, Nature Structural Biology.
[33] R. Sorenson,et al. Prolactin receptors and JAK2 in islets of Langerhans: an immunohistochemical analysis. , 1995, Endocrinology.
[34] Constitutive nuclear localization of Janus kinases 1 and 2. , 1996, Endocrinology.
[35] S. Pellegrini,et al. A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Constantinescu,et al. Structural Requirements of the Extracellular to Transmembrane Domain Junction for Erythropoietin Receptor Function* , 2005, Journal of Biological Chemistry.
[37] J. Kere,et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. , 2005, American journal of human genetics.
[38] H. Lodish,et al. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. , 2001, Molecular cell.
[39] T. Hakoshima,et al. Structural basis of adhesion‐molecule recognition by ERM proteins revealed by the crystal structure of the radixin—ICAM‐2 complex , 2003, The EMBO journal.
[40] P. Changelian,et al. The JAK3 inhibitor CP‐690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing , 2004, Journal of leukocyte biology.
[41] J. Tavernier,et al. Down-modulation of Type 1 Interferon Responses by Receptor Cross-competition for a Shared Jak Kinase* , 2001, The Journal of Biological Chemistry.
[42] A. Kraft,et al. The Amino-terminal Portion of the JAK2 Protein Kinase Is Necessary For Binding and Phosphorylation of the Granulocyte-Macrophage Colony-stimulating Factor Receptor β Chain (*) , 1995, The Journal of Biological Chemistry.
[43] O. Silvennoinen,et al. Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.
[44] P. Heinrich,et al. Studies on the Interleukin-6-type Cytokine Signal Transducer gp130 Reveal a Novel Mechanism of Receptor Activation by Monoclonal Antibodies* , 2000, The Journal of Biological Chemistry.
[45] R Berger,et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. , 1997, Science.
[46] P. Heinrich,et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.
[47] P. Heinrich,et al. Novel Role of Janus Kinase 1 in the Regulation of Oncostatin M Receptor Surface Expression* , 2002, The Journal of Biological Chemistry.
[48] Y. Kido,et al. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. , 1998, Molecular endocrinology.
[49] Jing Jiang,et al. Janus kinase 2 enhances the stability of the mature growth hormone receptor. , 2005, Endocrinology.
[50] P. Heinrich,et al. Janus Kinase (Jak) Subcellular Localization Revisited , 2004, Journal of Biological Chemistry.
[51] B. Rellahan,et al. The Amino-Terminal Src Homology 2 Domain of Phospholipase Cγ1 Is Essential for TCR-Induced Tyrosine Phosphorylation of Phospholipase Cγ1 , 1998, The Journal of Immunology.
[52] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[53] P. Doherty,et al. Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.
[54] W. Leonard,et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. , 1995, Science.
[55] Qingshan Li,et al. Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.
[56] P. Marynen,et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. , 1997, Blood.
[57] M. Ueffing,et al. Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.
[58] P. Heinrich,et al. Three Dileucine-like Motifs within the Interbox1/2 Region of the Human Oncostatin M Receptor Prevent Efficient Surface Expression in the Absence of an Associated Janus Kinase* , 2006, Journal of Biological Chemistry.
[59] H. Lodish,et al. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. , 2001, Molecular cell.
[60] P. Heinrich,et al. Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation. , 2002, The Biochemical journal.
[61] A. Sharpe,et al. Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3 , 1995, Science.
[62] A. Cumano,et al. Jak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis , 1998, Cell.
[63] D. Baltimore,et al. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.
[64] T. Taniguchi,et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[65] K. Yasukawa,et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[66] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[67] Sandra A. Moore,et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.
[68] Toshio Hakoshima,et al. Structural basis of the membrane‐targeting and unmasking mechanisms of the radixin FERM domain , 2000, The EMBO journal.
[69] Bernd Giese,et al. Long Term Association of the Cytokine Receptor gp130 and the Janus Kinase Jak1 Revealed by FRAP Analysis* , 2003, Journal of Biological Chemistry.
[70] S. Pellegrini,et al. The Janus kinase family of protein tyrosine kinases and their role in signaling , 1999, Cellular and Molecular Life Sciences CMLS.
[71] J. Rossjohn,et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.
[72] P. Heinrich,et al. Different protein turnover of interleukin-6-type cytokine signalling components. , 1999, European journal of biochemistry.
[73] H. Pircher,et al. Partial impairment of cytokine responses in Tyk2-deficient mice. , 2000, Immunity.
[74] M. Eck,et al. Crystal Structure of the FERM Domain of Focal Adhesion Kinase* , 2006, Journal of Biological Chemistry.
[75] J. Tavernier,et al. Contributions of leukemia inhibitory factor receptor and oncostatin M receptor to signal transduction in heterodimeric complexes with glycoprotein 130. , 1999, Journal of immunology.
[76] I. Kerr,et al. Mapping of a Region within the N Terminus of Jak1 Involved in Cytokine Receptor Interaction* , 2001, The Journal of Biological Chemistry.
[77] J. Johnston,et al. Autosomal SCID caused by a point mutation in the N‐terminus of Jak3: mapping of the Jak3–receptor interaction domain , 1999, The EMBO journal.
[78] S. Pestka,et al. A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses , 1997, Molecular and cellular biology.